Daily single-strength vs. thrice-weekly double-strength trimethoprim/ sulfamethoxazole for Pneumocystis jirovecii prophylaxis in kidney transplant recipients: A non-inferiority randomized control trial

Phase 4

Completed

• Conditions: renal transplantliver transplantheart transplant; cotrimoxazole; bactrim; Pneumocystis; Transplant Recipients

• Registration Number: TCTR20240329004
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-12-31
• Study Start: 2024-03-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

1. solid organ transplant recipient

Exclusion Criteria

1. trimethoprim/sulfamethoxazole allergy
2. underlying Glucose-6-Phosphate Dehydrogenase deficiency

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pneumocystis jirovecii pneumonia 24 months after drug initiation Chest X-ray, CT scan of chest, Sputum for PJP PCR or GMS, Expert opinion from transplant infectious physician or pulmonologist

Secondary Outcome Measures

Name	Time	Method
hepatitis after drugs initiation aspartate aminotransferase, alanine aminotransferase, symptoms (e.g., nausea, vomitting)